Breaking Finance News

Morgan Stanley announced Abbott Laboratories (NYSE:ABT), boosting its target price to $6.00 today

Abbott Laboratories (NYSE:ABT) had its target price raised to $6.00 by Morgan Stanley in a report released 10/19/2017. The upped price target suggests a potential downside of -0.89% based on the company's last closing price.

Yesterday Abbott Laboratories (NYSE:ABT) traded 1.29% higher at $55.93. The company’s 50-day moving average is $52.94 and its 200-day moving average is $48.37. The last closing price is up 15.29% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 9,044,529 shares of ABT traded hands, up from an average trading volume of 5,609,800

See Chart Below

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $56.60 with a price-earnings ratio of 78.11 ABT’s total market value is presently $0.

A total of 15 analysts have released a research note on ABT. Six analysts rating the company a strong buy, eight analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $46.73.

More About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.